Chardan Capital Reiterates Buy Rating for Solid Biosciences (NASDAQ:SLDB)

Share on StockTwits

Chardan Capital reaffirmed their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a report released on Monday morning, AnalystRatings.com reports. They currently have a $5.00 price target on the stock, down from their previous price target of $6.75.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Solid Biosciences from a hold rating to a sell rating in a research report on Friday, March 20th. Nomura increased their target price on Solid Biosciences from $6.00 to $10.00 and gave the company a buy rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Solid Biosciences has an average rating of Hold and a consensus price target of $8.63.

Shares of SLDB opened at $2.65 on Monday. The firm’s 50 day moving average is $3.12 and its 200-day moving average is $6.02. The stock has a market capitalization of $123.47 million, a P/E ratio of -0.90 and a beta of 1.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.72 and a quick ratio of 4.72. Solid Biosciences has a 12-month low of $1.96 and a 12-month high of $13.58.

Solid Biosciences (NASDAQ:SLDB) last released its earnings results on Thursday, March 12th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). As a group, equities research analysts forecast that Solid Biosciences will post -2.08 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. Millennium Management LLC increased its stake in Solid Biosciences by 842.3% in the 3rd quarter. Millennium Management LLC now owns 793,006 shares of the company’s stock valued at $8,199,000 after buying an additional 708,853 shares during the period. Spark Investment Management LLC boosted its stake in shares of Solid Biosciences by 138.7% during the 4th quarter. Spark Investment Management LLC now owns 138,800 shares of the company’s stock valued at $617,000 after buying an additional 80,660 shares during the period. State Street Corp grew its holdings in shares of Solid Biosciences by 16.8% during the 4th quarter. State Street Corp now owns 348,297 shares of the company’s stock valued at $1,550,000 after acquiring an additional 50,189 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Solid Biosciences by 19.8% during the 4th quarter. Geode Capital Management LLC now owns 275,214 shares of the company’s stock valued at $1,224,000 after acquiring an additional 45,465 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Solid Biosciences by 79.7% in the fourth quarter. Renaissance Technologies LLC now owns 58,040 shares of the company’s stock worth $258,000 after acquiring an additional 25,740 shares during the last quarter. Institutional investors and hedge funds own 57.83% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Further Reading: How does a dividend reinvestment plan work?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.